Historia
Kymos SL fue fundada en 2001 por un equipo de científicos de I+D con décadas de experiencia en el desarrollo farmacéutico, desde la investigación inicial hasta la formulación final y los ensayos de escalado para su comercialización. La empresa se estableció en el Parc Científic de Barcelona y experimentó una rápida expansión a pesar de la alta competencia. En 2011, Kymos asumió el equipo de inmunología de Ipsen Pharma para crear una división biológica pionera. En 2015, Kymos se trasladó a un nuevo laboratorio en el Parc Tecnològic del Vallès. En 2016, Kymos adquirió la CRO italiana Pharmaprogress. En 2018, su crecimiento constante requirió dos ampliaciones sucesivas con un nuevo edificio de oficinas y laboratorios. En 2020, Kymos adquirió la CRO alemana Proytic. En 2021, el Grupo Kymos está compuesto por una sede central de dos edificios, dos plantas europeas, 14 departamentos de laboratorio, 170 expertos altamente capacitados y 5.000 m² de instalaciones e instrumental de vanguardia. En 2023-2024 nuestra sede italiana se amplió con un nuevo edificio y se inició una ampliación del laboratorio en España.
| Our new building (1800 sqm) in Italy has been officially inaugurated at the start of the year, and all the equipment and projects have been moved to our new location in Monsano. Work has started on the lab extension in Spain (+600 sqm). |  |
| Kymos received the official certification by ANVISA (Agència Nacional de Vigilància Sanitária)for bioequivalence studies and was granted permission to participate in these studies for submission in Brazil. Work on Pharmaprogress new building has been finalized and we have started moving. |  |
| 2022 Kymos acquired a more spacious, convenient, and state-of-the-art building in the Ancona area. Parts of the building need renovation and there is still a lot of work ahead of us. But next year, Pharmaprogress can finally move into its new modern facilities. |  |
| Kymos is a very international company. Besides the three sites in different European countries, we also work for clients all over the world. In 2021 we exceeded for the first time the number of 40 countries in which our customers are located covering all continents. |  |
| In October 2020, Kymos merged with the German bioanalytical laboratory Prolytic GmbH located in Frankfurt. Prolytic had 16 people on staff and was specialisted in bioanalysis of small, large molecules as well as oligo nucleotides and pharmacokinetics. |  |
| In May, Kymos expanded again its facilities with new Analytical Development and Biopharmaceutical Testing laboratories. During the year, batch testing services for biosimilars and Asian clients are driving the company growth. |  |
| On April the FDA finished the inspection of Pharmaprogrees site in Ancona confirming this facility as eligible for marketing applications in the US. It has been a documentary inspection based on the previous AIFA (Agenzie Italiana del Farmaco) inspection thanks to the new Mutual Recognition Agreement existing between EMA e FDA. |  |
| In August, Prolytic moved to a larger and state of the art location at Weismüllerstraße 45. Doubling the size the 15-strong team now had 800 m² of laboratory and office space to offer the best bioanalytics and pharmacokinetics for its clients. |  |
| In July, Kymos expanded its facilities moving the offices to a new free-standing building close to the existing one. This new building has a training room, an archive, different meeting rooms and a cafeteria. |  |
| In July, Kymos underwent a general site inspection by the FDA. The inspection was completed succesfully and the corresponding EIR letter was issued. | |
| In November 2016, the company acquired a CRO in Italy called Pharmaprogress. The company was located in Ancona and had 8 people on staff. This company had a 700 m2 of laboratories for bioanalysis and analytical development of APIs and DPs. Nowadays, the company has been fully integrated into Kymos and now has 16 people on staff. |  |
| In January 2015, the company moved its facilities from Barcelona (Barcelona Science Park) to a free-standing buiding in Cerdanyola del Vallès (Vallès Technology Park). A brand-new laboratory was built, increasing the surface area from 650 m2 to 1,500 m2. This meant the company could boost turnover and grow its staff in 2015 and 2016. The same year Kymos obtained the importation autorization for medicinal products. Batch release services for marketing products were implemented. |  |
| In January 2012, Kymos reached an agreement to take over the immunology department of a former R&D centre that French multinational group IPSEN had in Barcelona. Thanks to this deal, Kymos was able to create a new biological division. Experienced staff, instruments and know-how were transferred to Kymos and both companies signed a long-term collaboration agreement to develop innovative drugs jointly. |  |
| In 2011, Kymos built a microbiology laboratory and extended its GMP certification to microbiological testing of non-sterile products. This certification was later extended further to cover sterile products in 2016. |  |
| In 2009, the company obtained GMP and Manufacturer authorization (partial manufacturer for quality control activities). From this point, Kymos moved all CMC activities (mainly analytical development and stability studies) to GMP quality system and begun to provide quality control services for APIs and DPs. |  |
| Pharmaprogress was GMP approved for chemical and physical testing by Italian Agency of Medicinal Products (AIFA) on January 2009. The last authorization is n. aM-119/2016 of July 22nd, 2016, relating the following tests on Human Medicinal Products: 1.6.3 GMP Quality Control chemical and physical Tests 1.6.3 GMP Quality Control chemical and physical Tests on Investigational Medicinal Products |
 |
| Prolytic was GLP certified by the Regierungspräsidium of Darmstadt in catergory 1 and 8. Category 1: Physical and chemical properties and determination of content Category 8: Analytical studies on biological materials |
 |
| Kymos obtained the GLP certification in 2002, at the very beginning. The first projects were in metabolism and bioanalysis. |  |
| Prolytic was founded. The roots of Prolytic GmbH can be traced back to Viatris GmbH & Co. KG, part of ASTA Medica AG, a pharmaceutical research company and formerly wholly owned subsidiary of Degussa AG. Viatris GmbH & Co. KG was sold to a finance investor who closed down the drug development sections “Bioanalysis” and “Pharmacokinetics.” An experienced group of scientists from these sections founded Prolytic GmbH in December 2002 with the aim of offering their abundant experience in bioanalysis and pharmacokinetics to clients in the pharmaceutical sector. |  |
| Pharmaprogress begun to provide services to third parties as CRO in 2001, despite the legal entity was previously founded in 1999. A fit-to-purpose laboratory of 700 m2 was built in Camerata Picena, near Ancona and it was GLP approved by Italian Health Authorities. The Company was founded by a former manager of an Italian pharmaceutical company. |  |
| Kymos was founded in 2001 by an R&D team from Menarini with more than 10 years of experience in research and deveelopment in the pharmaceutical industry. The staff members were clients before being suppliers, acquiring extensive knowledge of the pharma company requirements and priorities. This experience allowed Kymos to start-up the company quickly, despite being in this highly competitive market. The company was initially established in Barcelona Science Park, expanding from one to four different labs in just few years. |  |
Eventos
Únase a nosotros en nuestros próximos eventos.
Farmaforum: Madrid, ES | 17 y 18 de septiembre de 2025
Congreso de Bioproducción (BIOPC): Lyon, Francia | 22-23 de septiembre de 2025
Conferencia Internacional KoNECT-MOHW-MFDS: Seúl, Corea del Sur | 22-24 de septiembre de 2025
Festival de Biológicos: Basilea, Suiza | 30 de septiembre – 2 de octubre de 2025
BIOSPAÑA: Barcelona, ES | 07-09 octubre 2025
Congreso ESGCT: Sevilla, ES | 7-10 de octubre de 2025
BIOPLUS INTERPHEX COREA: Seúl, Corea del Sur | 15-17 de octubre de 2025
Reunión anual de la OET: Budapest, HU | 19-22 de octubre de 2025
CPHI 2025: Fráncfort, DE | 28-30 de octubre de 2025
I4ID MabDesign: Lyon, Francia | 13-14 de noviembre de 2025
Foro Europeo de Bioanálisis (EBF): Barcelona, España | 18-20 de noviembre de 2025
Congreso PharmaLab: Düsseldorf, DE | 24-26 de noviembre de 2025
BioFIT: Estrasburgo, Francia | 2-3 de diciembre de 2025
